Anti-CMV IgM titer predicts CMV disease after liver transplantation.(Royal Free and University College Medical School study cytomegalovirus)(Brief Article) From: Transplant News | Date: December 15, 2000 | COPYRIGHT 2000 Transplant Communications, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group.Copyright information

High levels of IgM antibody to cytomegalovirus (CMV) are an independent risk factor for the development of CMV infection after liver transplantation, according to researchers at the Royal Free and University College Medical School in London, UK.

Among 19 liver transplant recipients who developed CMV disease, 18 had high CMV-specific IgM antibody levels as measured by automated AxSYM assay. IgM was detected before CMV DNA (by PCR) in 2 patients, with both tests concurren...

Related newspaper, magazine, and journal articles from HighBeam Research

	Hoffman-La Roche receives FDA clearance to market oral ganciclovir for prevention of CMV Transplant News ; Hoffmann-La Roche, Nutley, NJ, announced it has received clearance from the Food and Drug Administration (FDA) to market oral ganciclovir (Cytovene (R) capsules) for the prevention of cytomegalovirus (CMV), a potentially life-threatening infection in recipients of solid organ transplants. The
	AIDS-related CMV: how to help yourself.(Pamphlet) Pamphlet by: National Institute of Allergy and Infectious Diseases ; What Is HIV Disease? HIV means Human Immunodeficiency Virus, which is a germ that can enter the body and cause AIDS (Acquired Immune Deficiency Syndrome). HIV attacks and kills certain cells of the body, especially those that protect us from disease. When too many of these cells have been
	Cytomegalovirus after kidney transplantation: a case review Progress in Transplantation ; Cytomegalovirus is the most common infectious complication in solid-organ transplant recipients. Despite the frequency of the problem, no commonly accepted approach to Cytomegalovirus prophylaxis and treatment exists. Because cytomegalovirus may lead to the modulation of the immune system sometimes
	Building acceptance for a costly product Pharmaceutical Executive ; To help make Medimmune's new, premium-priced product acceptable to costconscious health care organizations, a company team designed a software program that shows when and why paying more for a preventive therapy will pay off. The expanding influence of managed care has greatly limited what was once
	Combination therapy boosts CMV control Ophthalmology Times ; Oral ganciclovir used in conjunction with implant gets good results ATLANTA-The combination of oral ganciclovir administered with a ganciclovir intraocular implant has been shown to decrease the incidence of new cytomegalovirus (CMV) disease and delay progression of retinitis in patients with AIDS
	Quantitative PCR assay detects CMV DNA in transplant recipients.(Brief Article) Transplant News ; A new, highly sensitive quantitative PCR assay detected cytomegalovirus (CMV) DNA before symptoms developed in stem cell transplant recipients, according to researchers at the University of Washington in Seattle. The new assay was used to measure CMV DNA levels in the plasma of 15 stem cell
	CytoGam: Prophylaxis against CMV disease in various organ transplants Formulary ; CMV immune globulin (human) Medlmmune Inc The FDA has approved cytomegalovirus immune globulin intravenous (human) (CMV-IGIV) for prophylaxis against CMV disease associated with kidney, lung, liver, pancreas, and heart transplantation. Labeling notes that prophylactic CMV-IGIV should be considered
	Impact of Cytomegalovirus Match on Survival After Cardiac and Lung Transplantation The American Surgeon ; Acute cytomegalovirus (CMV) disease and indirect effects caused by the virus alter the outcome after solid organ transplantation. Long-term results after 54 lung and 139 cardiac transplants at a single center have been retrospectively analyzed with regard to CMV status. Standard CMV prophylaxis
	Event Brief of Q3 2006 ViroPharma Earnings Conference Call - Final Fair Disclosure Wire ; ... interests in the material; provided, however, that members of the news media may redistribute limited portions (less than 250 words ... interests in the material; provided, however, that members of the news media may redistribute limited portions (less than 250 words ...
	Q3 2006 ViroPharma Earnings Conference Call - Final Fair Disclosure Wire ; ... interests in the material; provided, however, that members of the news media may redistribute limited portions (less than 250 words ... interests in the material; provided, however, that members of the news media may redistribute limited portions (less than 250 words ...

See all results.